New approach aims to tame rogue immune attack with fewer side effects
NCT ID NCT06160791
Summary
This study is testing a new treatment combination for adults newly diagnosed with hemophagocytic lymphohistiocytosis (HLH), a rare and severe condition where the immune system attacks the body. Researchers want to see if adding the drug ruxolitinib to a reduced-dose version of standard HLH therapy can effectively control the disease while causing fewer side effects. The study will enroll 36 adults to evaluate how well the combination works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Irvine
RECRUITINGIrvine, California, 92697, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.